-- Legacy Gold Mines（股票代碼：LEGY.V）週二宣布，將於下個月啟動其位於愛達荷州的Baner金礦項目的第一階段鑽探計劃。 該公司表示，該鑽探計畫預計總鑽探深度為40,000英尺（12,194公尺），首先將進行約12,000英尺（3,658公尺）的鑽石鑽探，隨後進行約28,000英尺（8,536公尺）的反循環鑽探（RC）。 執行長Brian Hinchcliffe表示：“Legacy Gold團隊一直在與承包商密切合作，積極調配兩台鑽石鑽機，以期第一階段鑽探計劃能夠順利啟動，並充分利用季節性光照條件。” 「我們希望延續4月份完成的1000萬美元融資的勢頭，並立即啟動2026年的鑽探計劃，包括加密鑽探、延伸鑽探和勘探鑽探，目標是在2026年第四季度末或2027年第一季度初確定Baner礦區的首個礦產資源量。」 該公司股票在多倫多證券交易所創業板（TSX Venture Exchange）的最新交易中上漲0.05美元，至0.95美元。
Price: $0.95, Change: $+0.05, Percent Change: +5.56%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%